

Pharmacological Reports 2012, 64, 256–265 ISSN 1734-1140 Copyright © 2012 by Institute of Pharmacology Polish Academy of Sciences

Acute and repeated treatment with the 5-HT₇ receptor antagonist SB 269970 induces functional desensitization of 5-HT₇ receptors in rat hippocampus

Krzysztof Tokarski¹, Agnieszka Zelek-Molik², Beata Duszyńska³, Grzegorz Satała³, Bartosz Bobula¹, Magdalena Kusek¹, Piotr Chmielarz², Irena Nalepa², Grzegorz Hess^{1,4}

¹Department of Physiology, ²Department of Brain Biochemistry, ³Department of Medicinal Chemistry, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, PL 31-343 Kraków, Poland

⁴Institute of Zoology, Jagiellonian University, Gronostajowa 9, PL 30-387 Kraków, Poland

Correspondence: Krzysztof Tokarski, e-mail: ktok@if-pan.krakow.pl

Abstract:

Background: SB 269970, a 5-HT₇ receptor antagonist may produce a faster antidepressant-like effect in animal models, than do antidepressant drugs, e.g., imipramine. The present work was aimed at examining the effect of single and repeated (14 days) administration of SB 269970 on the 5-HT₇ receptor in the hippocampus.

Methods: The reactivity of 5-HT₇ receptors was determined using 5-carboxamidotryptamine (5-CT), which increased the bursting frequency of spontaneous epileptiform activity in hippocampal slices. Additionally, the effects of SB 269970 administration on the affinity and density of 5-HT₇ receptors were investigated using [³H]-SB 269970 and the influence of SB 269970 and imipramine on mRNA expression levels of G α_s and G α_{12} mRNA were studied using RT-qPCR.

Results: Acute and repeated treatment with SB 269970 led to attenuation of the excitatory effects of activation of 5-HT₇ receptors. Neither single nor repeated administration of SB 269970 changed the mean affinity of 5-HT₇ receptors for [³H]-SB 269970. Repeated, but not single, administration of SB 269970 decreased the maximum density of [³H]-SB 269970 binding sites. While administration of imipramine did not change the expression of mRNAs for $G\alpha_s$ and $G\alpha_{12}$ proteins after both single and repeated administration of SB 269970, a reduction in $G\alpha_s$ and $G\alpha_{12}$ mRNA expression levels was evident.

Conclusions: These findings indicate that even single administration of SB269970 induces functional desensitization of the 5-HT₇ receptor system, which precedes changes in the receptor density. This mechanism may be responsible for the rapid antidepressant-like effect of the 5-HT₇ antagonist in animal models.

Key words:

5-carboxamidotryptamine, adaptive changes, epileptiform activity, hippocampal slice, imipramine, SB 269970

Introduction

Serotonin (5-hydroxytryptamine, 5-HT), which acts as a neurotransmitter and/or a neuromodulator, is involved in a wide spectrum of physiological processes including sleep, cognition, sensory perception, motor activity, temperature regulation, appetite, hormone secretion, nociception, and sexual behavior (reviewed in: [30]). Dysfunctions of the serotonergic system are thought to be involved in the pathomechanism of depressive disorders. Besides other structures, the hippocampus plays an important role as a target for antidepressant and anxiolytic drugs [72] (reviewed in: [40, 47]). It has been suggested that a common result of different types of antidepressant therapies is an enhancement of 5-HT neurotransmission within the hippocampus (reviewed in: [9, 19, 27]).

The cellular effects of 5-HT are mediated by up to 14 distinct membrane receptor subtypes that may be expressed in various amounts in single neurons (reviewed in: [28, 29, 55]). Such a diversity permits the occurrence of different effects of 5-HT, including both, inhibitory and excitatory influence on neuronal networks. These mechanisms allow 5-HT to remodel neuronal excitability in a variety of cell types and neuronal circuits in a functionally appropriate manner. In the hippocampus, the most prominent modulatory effect of 5-HT is a 5-HT_{1A} receptor-mediated reduction of the excitability of pyramidal cells [1]. Another 5-HT receptor subtype which effectively modulates neuronal activity is the 5-HT₄ receptor whose activation increases excitability of hippocampal pyramidal cells [12, 15]. Adaptive modifications of serotonergic mechanisms modulating the functions of forebrain structures provide an effective mechanism of antidepressant therapies (reviewed in: [8, 36, 39]). In rats, repeated administration of tricyclic antidepressants (TCAs) enhances the inhibitory effect of 5-HT_{1A} receptor activation on the excitability of hippocampal pyramidal neurons [6, 13, 17, 35]. Adaptive changes induced by treatment with the TCA imipramine in rat hippocampus involve attenuation of the excitatory effect of 5-HT₄ receptor activation [7, 74]. Repeated administration of selective serotonin reuptake inhibitors (SSRIs) reduces the effectiveness of hippocampal 5-HT₄ receptor activation as well; however, at variance with the effects of TCA, the sensitivity of hippocampal 5-HT_{1A} receptors remains unchanged after treatment with SSRIs [7, 13, 14, 62] (reviewed in: [27]).

The 5-HT₇ receptor is the latest 5-HT receptor subtype to be identified [4, 54]. In the brain, the 5-HT₇ receptor is predominantly expressed in the thalamus, hippocampus, hypothalamus [48] and raphe nuclei [37]. This receptor has been implicated in mood regulation, circadian rhythmicity and sleep, the disturbances of which are evident in the course of affective disorders (reviewed in: [26, 61]). It has been well established that neuronal 5-HT₇ receptors activate adenylate cyclase through $G\alpha_s$ protein [34, 56]. Interestingly, it has been shown that activation of the 5-HT_{7A} receptor stimulates AC1 and AC8 Ca²⁺/calmodulindependent isoforms of adenylate cyclase which are insensitive to $G\alpha_s$ *in vivo* [3]. Moreover, it has been found that 5-HT₇ receptors may also activate $G\alpha_{12}$ protein [32]. On a cellular level, activation of the 5-HT₇ receptor decreases potassium conductances and increases the hyperpolarization-activated current I_h, and thus enhances the excitability of hippocampal pyramidal cells [2, 5, 65]. All these effects contribute to the 5-HT₇ receptor-mediated facilitation of hippocampal population spikes *in vivo* [38], as well as to the enhancement of epileptiform activity in disinhibited hippocampal slices *in vitro* [20, 49, 64].

It has been suggested that the modification of 5-HT_7 receptor activity resulting from chronic treatment with antidepressants may represent a mechanism underlying the therapeutic effect of these drugs [57] (reviewed in: [24, 26]). It is noteworthy that several psychotropic drugs exhibit high affinity for 5-HT_7 receptors [50, 52, 56, 59] (reviewed in: [33]). It has also been shown that certain antidepressants may exert some effects by acting directly on the 5-HT_7 receptor [46].

Recent studies have demonstrated a synergistic interaction between serotonin receptors antagonists and several antidepressant drugs [53, 67], including the specific 5-HT7 receptor antagonist SB 269970 [11, 70]. In animal models, inactivation or blockade of the 5-HT₇ receptor has been shown to induce antidepressant-like behavior [21, 25, 69]. Chronic treatment with antidepressants has also been shown to modify the reactivity of 5-HT₇ receptors. The downregulation of the 5-HT₇ receptor has been found to take place in rat suprachiasmatic nucleus of the hypothalamus after chronic treatment with TCAs including imipramine, and the SSRI – fluoxetine [46, 58]. Our earlier study indicated attenuation of the effects of activation of rat hippocampal 5-HT₇ receptors after treatment with the TCA imipramine and the SSRI citalopram [64]. These findings support the hypothesis that the 5-HT₇ receptor may be a target for the action of antidepressants drug. Moreover, blockade of this receptor opens up good possibilities for the treatment of depression [43] (reviewed in: [24, 40, 44]). It is widely known that the response to treatment with conventional antidepressants may be delayed for several weeks.

Previously, our electrophysiological study showed that repeated (14 times), but not single, imipramine administration diminished the reactivity of the 5-HT₇ receptor [64]. We also demonstrated that chronic treatment with imipramine modified neither the affinity of 5-HT₇ receptors to [³H]-SB 269970 nor the density of those receptors [63].

Download English Version:

https://daneshyari.com/en/article/2010926

Download Persian Version:

https://daneshyari.com/article/2010926

Daneshyari.com